Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statin Prices Likely To Remain High After Zocor Exclusivity Win

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.

You may also be interested in...



Generic Exclusivity On Delisted Patents Upheld By Appeals Court

In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.

Generic Exclusivity On Delisted Patents Upheld By Appeals Court

In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.

Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity

Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel